The focus of the “2014 AHA/ACC Guideline for the Management of Patients With Valvular
Heart Disease” 9, 10 (2014 VHD guideline) was the diagnosis and management of adult …

In July 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through November 2012, and other …

Background High-quality anticoagulation management is required to keep these narrow
therapeutic index medications as effective and safe as possible. This article focuses on the …

Randomised controlled trials are the best research design for decisions about the effect of
different interventions but randomisation does not, of itself, promote the applicability of a …

Studies have consistently evidenced the positive clinical, economic, and humanistic benefits
of pharmacist‐directed patient care in a variety of settings. Given the vast differences in …

Nesta atualização da Diretriz Brasileira de Valvopatias de 2011, são contemplados apenas
pacientes com valvopatia anatomicamente importante (estágios C e D da Diretriz da …

Objective: To evaluate the impact of pharmaceutical care (PC) interventions on health-
related quality of life (HRQoL) and determine sensitivity of HRQoL measures to PC services …

This guideline focuses primarily on valvular heart disease in the adult, with a separate
section dealing with specific recommendations for valve disorders in adolescents and young …

Objective: Although pharmacist‐participated warfarin therapy management (PWTM) has
been accepted and implemented in various parts of the world, the evidence demonstrating …